Eye member Myoclonia with or without absence offerings, eyelid-closing electrical encephalographic (EEG) paroxysm (epileptiform discharges and/or attacks), and light sensitivity are the three characteristics of idiopathic-generized epilepsia.
Important facts
- Jeavons Syndrome is a form of generalized epilepsy: It is characterized by eyelid Myoclonia (fast eyelid-oak), by the eye programs induced attacks and light sensitivity.
- The start usually occurs in childhood: Most cases start between the ages of 6 and 8, although some can be diagnosed later due to the wrong interpretation of symptoms.
Epileptic seizures are often activated by closing the eyes or exposure to bright lights: Flotensitivity plays an important role and EEG changes can be seen when eyes are closed or exposed to strobe-like stimuli.
Eyelid Myoclonia can be accompanied by short absence: Some patients experience a loss of consciousness that only lasts a few seconds, which can go unnoticed or are thought of for inattention.
Diagnosis is confirmed using EEG with eye assignment tests: The EEG shows characteristic generalized Spike-Wave discharges, especially when closing the eyes in a well-lit room.
Treatment usually includes anti-displacement medicines: Valproate and Levetiracetam are often used, but the treatment must be adjusted to individual response and severity of the attack.
Avoiding light triggers is part of management: Patients are advised to prevent flickering lights, to wear polarized lenses and reduce exposure to the screen.
Up to 13% of the generalized epilepsies can be caused by this disease. On the other hand, it is often ignored and subdivided. The majority of individuals have medically unmanageable epilepsy and attacks often last a lifetime.
Clinical characteristics and response to the treatment on Jeavons Syndrome
Background: Jeavons syndrome is a rare form of epilepsy characterized by light sensitivity, attacks caused by the closing of the eyelids and eyelid Myoclonia.
Treatment -resistant epilepsy is a frequent occurrence, although the clinical causes and prognostic variables that contribute to resistance to medicines have not been well studied.
Methods: Between January 1, 2000 and December 15, 2016 we identified 30 patients at a single institution that meet the diagnostic criteria of Jeavons syndrome. Jeavons Syndrome criteria include each of the following:
(1) Absence or absence-like myoclonia of the eyelids
(2) Paroxysms on Elektro andcepalography or attacks caused by the closure of the eyes
(3) Start of the attack after the age of 12 months. We have completed the history of epilepsy, anti -epileptic medication tests and treatment reaction.
Results: 80% of patients were female and the average age at the start of the attack was 7.3 years. The most frequent types of first attacks were absence charges (63%) and generalized tonic-clonic attacks (23%).
An average of 9.6 years passed before a diagnosis was made. 80% of patients had drug-resistant epilepsy and 70% had generalized tonic-clonic attacks after a median follow-up of two years.
The chance of developing drug-resistant epilepsy was increased by generalized tonic-clonic attacks and seizures other than absence supplying agents (P-values 0.049 and 0.03 respectively). To reduce attacks by more than 50%, valproic acid, lamotrigine, ethosuximide and Levetiracetam were the most successful.
Jeavons Syndrome Diagnosis is often postponed. In persons with Jeavons syndrome, generalized tonic clonic attacks and attacks other than absence transmitters can be indicators for drug-resistant epilepsy.
What causes Jeavons Syndrome
Epilepsy cannot be spread. Although various underlying diseases can cause epilepsy, about 50% of cases around the world the origin of the disease is still unknown.
The following subcategories of causes of epilepsy exist: structural, genetic, infectious, metabolic, immunologically and unknown. Examples include:
- Brain damage due to prenatal or perinatal causes (eg a loss of oxygen or trauma during birth, low birth weight);
- congenital abnormalities or genetic disorders with corresponding brain crimes;
- a serious head injury;
- a stroke that limits the amount of oxygen to the brain;
- An infection of the brain such as meningitis, encephalitis or neurocysticercosis,
- certain genetic syndromes; And
- A brain tumor.
Drawing and Symptoms of Jeavons Syndrome
Epilations can have different characteristics, depending on where the disruption initially appears in the brain and how far it develops. Temporary symptoms include loss of consciousness or consciousness, as well as limitations in motion, mood or other cognitive processes, as well as a sense of sense (including vision, hearing and taste).
Both physical issues (such as fractures and bruises of attack-related traumas) and psychological issues, such as anxiety and sorrow, are more common in people with epilepsy.
Similar to this, patients with epilepsy have a risk of dying prematurely that is up to three times greater than those of the general population, with rural regions and low and middle income countries the largest percentages of early mortality.
Many of the epilepsy-related causes of mortality, in particular in low and middle income countries, can be avoided, including falls, drowning, burns and extensive attacks.
Management and treatment
Epilations are manageable. With the correct administration of anti -disease drugs, up to 70% of patients with epilepsy can be attacked free.
When considering the anti-displacement medication, relevant clinical, social and personal variables must be taken into account after two years without attacks.
The two most reliable indicators for repetition of attacks are a well -known etiology for seizure and an abnormal electrosencefalography (EEG) pattern.
- About 75 percent of epileptic patients may not receive the necessary care in low -income countries. The “treatment gap” refers to this.
- Anti-displacement medicines are not available on a large scale in many countries with low and middle income.
- According to recent research, there are usually less than 50% of generic anti-disease medicines available in the public sector of low and middle income. This can make it difficult to get treatment.
- Most epileptic patients can be diagnosed and treated on the basis of health care level without the need for advanced technology.
- According to WHO pilot studies, teaching primary care practitioners can considerably closing the treatment gap for the disorder.
- Patients who respond poorly to pharmacological therapies can benefit from surgery.
Jeavons Syndrome Prevention
About 25% of the epilepsy cases can be avoided.
- The best strategy to prevent post -traumatic epilepsy is to prevent head injury.
- Correct prenatal care can reduce the number of new authorities of epilepsy due to birth trauma.
- The risk of Febre attacks can be reduced by using medicines and other techniques to lower the body temperature of a sick child.
- The reduction of cardiovascular risk factors, such as actions to prevent or manage high blood pressure, diabetes and obesity, and abstain from cigarettes and excessive alcohol consumption, is the main purpose of preventing epilepsy to stroke.
- Epilepsy is often caused by diseases of the central nervous system in tropical areas, which are usually inhabited by low and middle income. The prevalence of epilepsy, as caused by neurocysticercosis, can be reduced worldwide by the elimination of parasites in these environments and education about how to prevent infections.
Conclusion:
Every year, Epilepsy affects an estimated 5 million people worldwide. It is assumed that epilepsy is diagnosed annually in 49 out of 100,000 people in countries with a high income. This number can reach 139 per 100,000 in countries with low and middle income.
This is probably because endemic diseases such as malaria and neurocysticercosis occur more often, traffic accidents and birth elles are more common and there are differences in the medical infrastructure, the availability of preventive health programs and access to treatment. Almost 80% of patients with epilepsy live in countries with low and middle income.
References
Panayiotopoulos CP. “Jeavons Syndrome: a pure reflex epilepsy.” Epilepsy. https://doi.org/10.1111/J.1528-1167.2001.tb06159.x
Epilepsy Foundation. “Jeavons syndrome (eyelid myoclonia).” Epilepsy.com. https://www.epilepsy.com/epilepsy/types/jeavons syndrome
National Organization for Rare Disorders (Nord). “Eyelid Myoclonia in absence.” rarediseases.org. https://rarediseases.org/rare-diseases/eyelid-myoclonia-with-absences/
National Institute of Neurological Disorders and Stroke (Ninds). “Epilepsy information page.” ninds.nih.gov. https://www.nih.gov/health-information/disorders/epilepsie
#Jeavons #Syndrome #eyelid #Myoclonia #symptoms #treatment